• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Owlet Launches New Sleep Wearable for Kids up to 5 Years Old

Share:

March 15, 2022

Baby wearable company Owlet is expanding its scope to young children with the launch of Owlet Dream Sock Plus, which is intended for children up to 5 years of age. Previously its smart socks only covered children up 1o 18 months.

The technology, which was designed to give insights into a child’s sleep, can be around a child’s foot. The wearable can send data via Bluetooth to a caregiver’s Owlet Dream app about a child’s wakings, heart rate, and movement. Caregivers can tap into the app to see sleep status and statistics over time.

The app also includes content about a baby’s first 18 weeks and an asleep learning program for children up to a year old. Owlet is selling the Dream Sock Plus for $359, which comes with the sock sensor, a base station, and three sizes of fabric socks. The company specified that the tech is intended for children weighing up to 55 pounds.

WHY IT MATTERS

According to the CDC, sleep is important to prevent Type 2 diabetes, obesity, poor mental health, attention problems, and injuries. The agency recommends that toddlers get between 11 and 14 hours of sleep a day, and preschoolers get 10-13 hours.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Owlet is pitching this new tool as a way to help keep track of young children’s sleep.

“The need for a good night’s sleep doesn’t end after 18 months, and with the Dream Sock Plus, we’re providing a solution that parents have long been asking Owlet for,” said Kurt Workman, co-founder, and CEO of Owlet.

“We are thrilled to be able to offer the award-winning Dream Sock technology to families for use over a much longer period of time. Having monitored over one million babies, Owlet’s mission has always been to empower parents with the tools, training, and support they need to help keep their baby happy and healthy.”

THE LARGER TREND

In 2021, Owlet went public on the New York Stock Exchange via a SPAC merger with Sandbridge Acquisition Corp.

It hasn’t been all smooth sailing for the Utah-based startup. In November, the company pulled its connected-sock wearables from the market following an October FDA warning letter that the company was out of regulatory compliance. Following this announcement, investors filed a class-action lawsuit against the company alleging that it failed to disclose the socks that needed FDA clearance before hitting the market.

The company’s stock has taken a tumble since the regulatory issues surfaced. The stock is trading for roughly $2.20, down from its all-time high of $10.77 in February 2021.

In January, the company released a new baby sleep monitoring system, the Dream Duo, which was designed to help track a baby’s sleep. This system made fewer promises about the health metrics it could track compared with the predecessor that was pulled.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Pharmaceutical Excipients Market with COVID-19 Impact Analysis, Global Industry Analysis, Growth Opportunities, Detailed Overview and 2026 Forecast StudyPharmaceutical Excipients Market with COVID-19 Impact Analysis, Global Industry Analysis, Growth Opportunities, Detailed Overview and 2026 Forecast Study
  • Bayer And Arvinas To Collaborate On Human PROTAC® Therapies And Launch A Separate Joint Venture To Develop Agricultural PROTAC® ApplicationsBayer And Arvinas To Collaborate On Human PROTAC® Therapies And Launch A Separate Joint Venture To Develop Agricultural PROTAC® Applications
  • Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium BenzoateAcer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
  • ANP Technologies, Inc. Terminates Merger Negotiations with Sorrento Therapeutics, Inc.ANP Technologies, Inc. Terminates Merger Negotiations with Sorrento Therapeutics, Inc.
  • Sony Unveils Wearable for Secure Mobile Health & Remote MonitoringSony Unveils Wearable for Secure Mobile Health & Remote Monitoring
  • Healthplex Acquired By Affiliates Of MCNA DentalHealthplex Acquired By Affiliates Of MCNA Dental
  • Eurobio Scientific acquires Dendritics, a company specializing in antibody development and manufactureEurobio Scientific acquires Dendritics, a company specializing in antibody development and manufacture
  • Machine Learning Algorithm Can Predict Which Cardiac Patients Are High-Risk Post DischargeMachine Learning Algorithm Can Predict Which Cardiac Patients Are High-Risk Post Discharge

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications